Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 3001 to 3015 of 8933 results

  1. Molecular testing strategies for Lynch syndrome in people with colorectal cancer (HTG430)

    Evidence-based recommendations on using immunohistochemistry or microsatellite instability testing to guide further testing for Lynch syndrome in people with colorectal cancer.

  2. High-throughput non-invasive prenatal testing for fetal RHD genotype (HTG420)

    Evidence-based recommendations on high-throughput non-invasive prenatal testing (NIPT) for fetal RHD genotype.

  3. SepsiTest assay for rapidly identifying bloodstream bacteria and fungi (HTG400)

    Evidence-based recommendations on the SepsiTest assay for rapidly identifying bloodstream bacteria and fungi.

  4. Tests in secondary care to identify people at high risk of ovarian cancer (HTG453)

    Evidence-based recommendations on tests in secondary care to identify people at high risk of ovarian cancer. The tests are the IOTA ADNEX model, Overa (MIA2G), RMI I (at thresholds other than 250), ROMA and IOTA Simple Rules.

  5. Ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections (AMR1)

    Evidence-based recommendations on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections.

  6. Cefiderocol for treating severe drug-resistant gram-negative bacterial infections (AMR2)

    Evidence-based recommendations on cefiderocol for treating severe drug-resistant gram-negative bacterial infections.

  7. Artificial intelligence (AI)-derived computer-aided detection (CAD) software for detecting and measuring lung nodules in CT scan images (HTG687)

    Evidence-based recommendations on artificial intelligence (AI)-derived computer-aided detection (CAD) software for detecting and measuring lung nodules in CT scan images.

  8. Point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast (HTG530)

    Evidence-based recommendations on point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast. The tests are ABL800 FLEX, i-STAT Alinity and StatSensor, ABL90 FLEX PLUS, Dri chem NX500, epoc Blood Analysis System, and Piccolo Xpress.

  9. Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies: early value assessment (HTG665)

    Early value assessment (EVA) guidance on the Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies.

  10. ProKnow cloud-based system for radiotherapy data storage, communication and management: early value assessment (HTG664)

    Early value assessment (EVA) guidance on the ProKnow cloud-based system for radiotherapy data storage, communication and management.

  11. CaRi-Heart for predicting cardiac risk in suspected coronary artery disease: early value assessment (HTG663)

    Early value assessment (EVA) guidance on CaRi-Heart for predicting cardiac risk in suspected coronary artery disease.

  12. Guided self-help digital cognitive behavioural therapy for children and young people with mild to moderate symptoms of anxiety or low mood: early value assessment (HTG660)

    Early value assessment (EVA) guidance on guided self-help digital cognitive behavioural therapy for children and young people with mild to moderate symptoms of anxiety or low mood.

  13. Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment (HTG748)

    Early value assessment (EVA) guidance on digital therapy for chronic tic disorders and Tourette syndrome.

  14. Point-of-care tests for urinary tract infections to improve antimicrobial prescribing: early value assessment (HTG674)

    Early value assessment (EVA) guidance on point-of-care tests for urinary tract infections to improve antimicrobial prescribing.

  15. Virtual reality technologies for treating agoraphobia or agoraphobic avoidance: early value assessment (HTG701)

    Early value assessment (EVA) guidance on virtual reality technologies for treating agoraphobia or agoraphobic avoidance.